$OCX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in OncoCyte Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in OncoCyte Corp. Get notifications about new insider transactions in OncoCyte Corp for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 14 2021 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | X | 3.00 | 6,993 | 20,979 | 0 | |
Jun 14 2021 | OCX | OncoCyte Corp | Last Andrew J. | Director | Buy | X | 3.00 | 6,993 | 20,979 | 30,170 | 23.2 K to 30.2 K (+30.17 %) |
Apr 30 2021 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | M | 0.00 | 20,000 | 0 | 0 | |
Apr 30 2021 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Payment of Exercise | F | 0.00 | 4,620 | 0 | 62,080 | 66.7 K to 62.1 K (-6.93 %) |
Apr 30 2021 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Buy | M | 0.00 | 20,000 | 0 | 66,700 | 46.7 K to 66.7 K (+42.83 %) |
Mar 22 2021 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Chief Executive Off ... | Buy | P | 4.79 | 11,000 | 52,702 | 113,698 | 102.7 K to 113.7 K (+10.71 %) |
Mar 01 2021 | OCX | OncoCyte Corp | Sundar Padmavathi | Chief Commercial Of ... | Option Exercise | A | 5.34 | 255,000 | 1,361,700 | 255,000 | |
Feb 09 2021 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 4.50 | 600,000 | 2,700,000 | 16,776,484 | 16.2 M to 16.8 M (+3.71 %) |
Jan 22 2021 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 3.42 | 1,460,280 | 4,999,999 | 16,176,484 | 14.7 M to 16.2 M (+9.92 %) |
Dec 28 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | M | 1.34 | 65,271 | 87,463 | 0 | |
Dec 28 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | M | 1.34 | 1,237 | 1,658 | 65,271 | |
Dec 28 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Buy | M | 1.34 | 65,271 | 87,463 | 384,111 | 318.8 K to 384.1 K (+20.47 %) |
Dec 28 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Sell | S | 2.55 | 900 | 2,295 | 318,840 | 319.7 K to 318.8 K (-0.28 %) |
Dec 28 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Buy | M | 1.34 | 1,237 | 1,658 | 319,740 | 318.5 K to 319.7 K (+0.39 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | M | 1.34 | 10,516 | 14,091 | 66,508 | |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | M | 1.34 | 47,976 | 64,288 | 77,024 | |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Sell | S | 0.00 | 7,652 | 0 | 318,503 | 326.2 K to 318.5 K (-2.35 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Buy | M | 1.34 | 10,516 | 14,091 | 326,155 | 315.6 K to 326.2 K (+3.33 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Sell | S | 2.54 | 5,148 | 13,076 | 315,639 | 320.8 K to 315.6 K (-1.60 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Sell | S | 0.00 | 30,000 | 0 | 320,787 | 350.8 K to 320.8 K (-8.55 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Buy | M | 1.34 | 47,976 | 64,288 | 350,787 | 302.8 K to 350.8 K (+15.84 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | M | 1.34 | 10,516 | 14,091 | 66,508 | |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | M | 1.34 | 47,976 | 64,288 | 77,024 | |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Sell | S | 0.00 | 7,652 | 0 | 318,503 | 326.2 K to 318.5 K (-2.35 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Buy | M | 1.34 | 10,516 | 14,091 | 326,155 | 315.6 K to 326.2 K (+3.33 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Sell | S | 2.54 | 5,148 | 13,076 | 315,639 | 320.8 K to 315.6 K (-1.60 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Sell | S | 0.00 | 30,000 | 0 | 320,787 | 350.8 K to 320.8 K (-8.55 %) |
Dec 23 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Buy | M | 1.34 | 47,976 | 64,288 | 350,787 | 302.8 K to 350.8 K (+15.84 %) |
Dec 15 2020 | OCX | OncoCyte Corp | Sundar Padmavathi | SVP, Marketing & Ma ... | Grant | A | 0.00 | 4,177 | 0 | 4,177 | 0 to 4.2 K |
Dec 15 2020 | OCX | OncoCyte Corp | HESTERBERG LYNDAL K. | CSO | Grant | A | 0.00 | 6,603 | 0 | 7,477 | 874 to 7.5 K (+755.49 %) |
Dec 15 2020 | OCX | OncoCyte Corp | Arno Andrew | Director | Grant | A | 0.00 | 9,602 | 0 | 112,049 | 102.4 K to 112 K (+9.37 %) |
Dec 15 2020 | OCX | OncoCyte Corp | Last Andrew J. | Director | Grant | A | 0.00 | 16,184 | 0 | 23,177 | 7 K to 23.2 K (+231.43 %) |
Dec 15 2020 | OCX | OncoCyte Corp | Parker Albert P | COO | Grant | A | 0.00 | 5,586 | 0 | 10,586 | 5 K to 10.6 K (+111.72 %) |
Dec 15 2020 | OCX | OncoCyte Corp | Ross Douglas T. | CMO | Grant | A | 0.00 | 5,317 | 0 | 5,317 | 0 to 5.3 K |
Dec 15 2020 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Grant | A | 0.00 | 18,416 | 0 | 70,863 | 52.4 K to 70.9 K (+35.11 %) |
Dec 15 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Grant | A | 0.00 | 5,909 | 0 | 302,811 | 296.9 K to 302.8 K (+1.99 %) |
Dec 15 2020 | OCX | OncoCyte Corp | Levine Mitchell S | CFO | Grant | A | 0.00 | 10,121 | 0 | 46,700 | 36.6 K to 46.7 K (+27.67 %) |
Aug 05 2020 | OCX | OncoCyte Corp | Parker Albert P | Chief Operating Off ... | Buy | P | 1.33 | 5,000 | 6,648 | 5,000 | 0 to 5 K |
Aug 05 2020 | OCX | OncoCyte Corp | KALAJIAN TONY T | Sr.VP/Chief Account ... | Buy | P | 1.31 | 5,000 | 6,533 | 15,000 | 10 K to 15 K (+50.00 %) |
Aug 04 2020 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Chief Executive Off ... | Buy | P | 1.35 | 40,000 | 53,880 | 102,698 | 62.7 K to 102.7 K (+63.80 %) |
Aug 04 2020 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Buy | P | 1.32 | 10,000 | 13,200 | 36,579 | 26.6 K to 36.6 K (+37.62 %) |
Jun 19 2020 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Option Exercise | A | 2.38 | 62,000 | 147,560 | 62,000 | |
Jun 19 2020 | OCX | OncoCyte Corp | GRIFFITH MELINDA | Director | Option Exercise | A | 2.38 | 57,000 | 135,660 | 57,000 | |
Jun 19 2020 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | A | 2.38 | 57,000 | 135,660 | 57,000 | |
Jun 19 2020 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | A | 2.38 | 57,000 | 135,660 | 57,000 | |
Jun 19 2020 | OCX | OncoCyte Corp | Arno Andrew | Director | Option Exercise | A | 2.38 | 57,000 | 135,660 | 57,000 | |
May 12 2020 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Chief Executive Off ... | Option Exercise | A | 0.00 | 106,221 | 0 | 106,221 | |
Apr 30 2020 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Apr 28 2020 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 2.27 | 1,050,000 | 2,383,500 | 14,716,204 | 13.7 M to 14.7 M (+7.68 %) |
Apr 20 2020 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | M | 0.00 | 20,000 | 0 | 0 | |
Apr 20 2020 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Payment of Exercise | F | 0.00 | 6,916 | 0 | 26,579 | 33.5 K to 26.6 K (-20.65 %) |
Apr 20 2020 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Buy | M | 0.00 | 20,000 | 0 | 33,495 | 13.5 K to 33.5 K (+148.20 %) |
Apr 01 2020 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | CEO and President | Buy | P | 2,372.00 | 18,000 | 42,696,000 | 62,698 | 44.7 K to 62.7 K (+40.27 %) |
Apr 01 2020 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | CEO and President | Buy | P | 2.26 | 27,216 | 61,454 | 44,698 | 17.5 K to 44.7 K (+155.68 %) |
Feb 12 2020 | OCX | Oncocyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 2.63 | 204,000 | 536,520 | 204,000 | |
Feb 12 2020 | OCX | Oncocyte Corp | KALAJIAN TONY T | SVP, Chief Accounti ... | Option Exercise | A | 2.63 | 204,000 | 536,520 | 204,000 | |
Feb 12 2020 | OCX | Oncocyte Corp | Parker Albert P | Chief Operating Off ... | Option Exercise | A | 2.63 | 204,000 | 536,520 | 204,000 | |
Feb 12 2020 | OCX | Oncocyte Corp | Sundar Padma | SVP, Marketing & Ma ... | Option Exercise | A | 2.63 | 255,000 | 670,650 | 255,000 | |
Jan 06 2020 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 2.16 | 623,090 | 1,343,382 | 13,666,204 | 13 M to 13.7 M (+4.78 %) |
Jan 06 2020 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 2.16 | 768,376 | 1,656,619 | 13,043,114 | 12.3 M to 13 M (+6.26 %) |
Nov 15 2019 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 1.70 | 1,176,471 | 2,000,001 | 12,274,738 | 11.1 M to 12.3 M (+10.60 %) |
Sep 18 2019 | OCX | OncoCyte Corp | Arno Andrew | Director | Buy | P | 2.16 | 50,000 | 108,130 | 102,447 | 52.4 K to 102.4 K (+95.33 %) |
Sep 16 2019 | OCX | OncoCyte Corp | KALAJIAN TONY T | SVP-Chief Accountin ... | Buy | P | 1.98 | 10,000 | 19,800 | 10,000 | 0 to 10 K |
Sep 13 2019 | OCX | OncoCyte Corp | Lineage Cell Therapeutics, Inc ... | 10% Owner | Sell | S | 1.66 | 4,000,000 | 6,640,000 | 8,424,244 | 12.4 M to 8.4 M (-32.20 %) |
Sep 13 2019 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 1.66 | 2,000,000 | 3,320,000 | 11,098,267 | 9.1 M to 11.1 M (+21.98 %) |
Sep 12 2019 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Buy | P | 2.01 | 10,000 | 20,060 | 10,000 | 0 to 10 K |
Jul 19 2019 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Option Exercise | A | 2.12 | 50,000 | 106,000 | 50,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Option Exercise | A | 2.12 | 50,000 | 106,000 | 50,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | MOHANTY ADITYA P. | Director | Option Exercise | A | 2.12 | 45,000 | 95,400 | 45,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | MOHANTY ADITYA P. | Director | Option Exercise | A | 2.12 | 45,000 | 95,400 | 45,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | A | 2.12 | 45,000 | 95,400 | 45,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | A | 2.12 | 45,000 | 95,400 | 45,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | A | 2.12 | 45,000 | 95,400 | 45,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | A | 2.12 | 45,000 | 95,400 | 45,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | Arno Andrew | Director | Option Exercise | A | 2.12 | 45,000 | 95,400 | 45,000 | |
Jul 19 2019 | OCX | OncoCyte Corp | Arno Andrew | Director | Option Exercise | A | 2.12 | 45,000 | 95,400 | 45,000 | |
Jul 05 2019 | OCX | OncoCyte Corp | BIOTIME INC | 10% Owner | Sell | S | 2.00 | 2,250,000 | 4,500,000 | 12,424,244 | 14.7 M to 12.4 M (-15.33 %) |
Jul 03 2019 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Chief Executive Off ... | Option Exercise | A | 2.51 | 950,000 | 2,384,500 | 950,000 | |
Jul 02 2019 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 2.00 | 1,000,000 | 2,000,000 | 9,098,267 | 8.1 M to 9.1 M (+12.35 %) |
Mar 18 2019 | OCX | OncoCyte Corp | ANNETT WILLIAM | President and CEO | Option Exercise | A | 3.52 | 390,000 | 1,372,800 | 390,000 | |
Mar 18 2019 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Mar 18 2019 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 3.52 | 245,000 | 862,400 | 245,000 | |
Mar 18 2019 | OCX | OncoCyte Corp | HESTERBERG LYNDAL K. | Chief Scientific Of ... | Option Exercise | A | 3.52 | 350,000 | 1,232,000 | 350,000 | |
Mar 18 2019 | OCX | OncoCyte Corp | Parker Albert P | Chief Operating Off ... | Option Exercise | A | 3.52 | 200,000 | 704,000 | 200,000 | |
Feb 27 2019 | OCX | OncoCyte Corp | MOHANTY ADITYA P. | Director | Option Exercise | A | 3.80 | 33,750 | 128,250 | 33,750 | |
Feb 12 2019 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 3.75 | 533,333 | 1,999,999 | 8,098,267 | 7.6 M to 8.1 M (+7.05 %) |
Sep 04 2018 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | A | 2.40 | 45,000 | 108,000 | 45,000 | |
Sep 04 2018 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | A | 2.40 | 45,000 | 108,000 | 45,000 | |
Sep 04 2018 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Director | Option Exercise | A | 2.40 | 45,000 | 108,000 | 45,000 | |
Sep 04 2018 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Option Exercise | A | 2.40 | 50,000 | 120,000 | 50,000 | |
Sep 04 2018 | OCX | OncoCyte Corp | Arno Andrew | Director | Option Exercise | A | 2.40 | 45,000 | 108,000 | 45,000 | |
Jul 31 2018 | OCX | OncoCyte Corp | ANNETT WILLIAM | President and CEO | Option Exercise | P | 3.00 | 3,500 | 10,500 | 3,500 | |
Jul 31 2018 | OCX | OncoCyte Corp | ANNETT WILLIAM | President and CEO | Buy | P | 0.00 | 3,500 | 0 | 3,500 | 0 to 3.5 K |
Jul 31 2018 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Director | Option Exercise | P | 3.00 | 17,482 | 52,446 | 17,482 | |
Jul 31 2018 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Director | Buy | P | 0.00 | 17,482 | 0 | 17,482 | 0 to 17.5 K |
Jul 31 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | P | 3.00 | 3,495 | 10,485 | 3,495 | |
Jul 31 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Buy | P | 0.00 | 3,495 | 0 | 3,495 | 0 to 3.5 K |
Jul 31 2018 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Option Exercise | P | 3.00 | 52,447 | 157,341 | 52,447 | |
Jul 31 2018 | OCX | OncoCyte Corp | ANNETT WILLIAM | President and CEO | Option Exercise | P | 3.00 | 3,500 | 10,500 | 3,500 | |
Jul 31 2018 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Buy | P | 0.00 | 52,447 | 0 | 52,447 | 0 to 52.4 K |
Jul 31 2018 | OCX | OncoCyte Corp | ANNETT WILLIAM | President and CEO | Buy | P | 0.00 | 3,500 | 0 | 3,500 | 0 to 3.5 K |
Jul 31 2018 | OCX | OncoCyte Corp | HESTERBERG LYNDAL K. | Sr VP, Research & D ... | Option Exercise | P | 3.00 | 874 | 2,622 | 874 | |
Jul 31 2018 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Director | Option Exercise | P | 3.00 | 17,482 | 52,446 | 17,482 | |
Jul 31 2018 | OCX | OncoCyte Corp | HESTERBERG LYNDAL K. | Sr VP, Research & D ... | Buy | P | 0.00 | 874 | 0 | 874 | 0 to 874 |
Jul 31 2018 | OCX | OncoCyte Corp | ANDREWS RONALD ASBURY | Director | Buy | P | 0.00 | 17,482 | 0 | 17,482 | 0 to 17.5 K |
Jul 31 2018 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | P | 3.00 | 6,993 | 20,979 | 6,993 | |
Jul 31 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | P | 3.00 | 3,495 | 10,485 | 3,495 | |
Jul 31 2018 | OCX | OncoCyte Corp | Last Andrew J. | Director | Buy | P | 0.00 | 6,993 | 0 | 6,993 | 0 to 7 K |
Jul 31 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Buy | P | 0.00 | 3,495 | 0 | 3,495 | 0 to 3.5 K |
Jul 31 2018 | OCX | OncoCyte Corp | Arno Andrew | Director | Option Exercise | P | 3.00 | 52,447 | 157,341 | 52,447 | |
Jul 31 2018 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Option Exercise | P | 3.00 | 52,447 | 157,341 | 52,447 | |
Jul 31 2018 | OCX | OncoCyte Corp | Arno Andrew | Director | Buy | P | 0.00 | 52,447 | 0 | 52,447 | 0 to 52.4 K |
Jul 31 2018 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Buy | P | 0.00 | 52,447 | 0 | 52,447 | 0 to 52.4 K |
Jul 31 2018 | OCX | OncoCyte Corp | HESTERBERG LYNDAL K. | Sr VP, Research & D ... | Option Exercise | P | 3.00 | 874 | 2,622 | 874 | |
Jul 31 2018 | OCX | OncoCyte Corp | HESTERBERG LYNDAL K. | Sr VP, Research & D ... | Buy | P | 0.00 | 874 | 0 | 874 | 0 to 874 |
Jul 31 2018 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | P | 3.00 | 6,993 | 20,979 | 6,993 | |
Jul 31 2018 | OCX | OncoCyte Corp | Last Andrew J. | Director | Buy | P | 0.00 | 6,993 | 0 | 6,993 | 0 to 7 K |
Jul 31 2018 | OCX | OncoCyte Corp | Arno Andrew | Director | Option Exercise | P | 3.00 | 52,447 | 157,341 | 52,447 | |
Jul 31 2018 | OCX | OncoCyte Corp | Arno Andrew | Director | Buy | P | 0.00 | 52,447 | 0 | 52,447 | 0 to 52.4 K |
Jun 15 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 2.55 | 45,000 | 114,750 | 45,000 | |
Jun 11 2018 | OCX | OncoCyte Corp | MECHEM KRISTINE C. | VP of Marketing | Option Exercise | A | 2.85 | 50,000 | 142,500 | 50,000 | |
Jun 04 2018 | OCX | OncoCyte Corp | MECHEM KRISTINE C. | VP of Marketing | Option Exercise | A | 2.35 | 125,000 | 293,750 | 125,000 | |
Jun 04 2018 | OCX | OncoCyte Corp | HESTERBERG LYNDAL K. | Sr VP, Research & D ... | Option Exercise | A | 2.35 | 150,000 | 352,500 | 150,000 | |
Jun 01 2018 | OCX | OncoCyte Corp | ANNETT WILLIAM | President and CEO | Option Exercise | A | 2.35 | 180,000 | 423,000 | 180,000 | |
Jun 01 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 2.35 | 125,000 | 293,750 | 125,000 | |
Jun 01 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 2.35 | 125,000 | 293,750 | 125,000 | |
Jun 01 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 2.35 | 50,000 | 117,500 | 50,000 | |
Jun 01 2018 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 2.35 | 50,000 | 117,500 | 50,000 | |
Mar 30 2018 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | P | 1.26 | 3,968,254 | 5,000,000 | 7,564,934 | 3.6 M to 7.6 M (+110.33 %) |
Nov 17 2017 | OCX | OncoCyte Corp | Levine Mitchell S | Chief Financial Off ... | Option Exercise | A | 5.90 | 200,000 | 1,180,000 | 200,000 | |
Jul 25 2017 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Option Exercise | J | 3.25 | 270,000 | 877,500 | 270,000 | |
Jul 25 2017 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Option Exercise | X | 3.25 | 540,000 | 1,755,000 | 573,461 | |
Jul 25 2017 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | X | 3.25 | 540,000 | 1,755,000 | 3,596,680 | 3.1 M to 3.6 M (+17.67 %) |
Jun 20 2017 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | A | 5.10 | 20,000 | 102,000 | 20,000 | |
Jun 20 2017 | OCX | OncoCyte Corp | Last Andrew J. | Director | Option Exercise | A | 5.10 | 6,520 | 33,252 | 6,520 | |
Jun 19 2017 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Option Exercise | A | 5.10 | 20,000 | 102,000 | 20,000 | |
Jun 19 2017 | OCX | OncoCyte Corp | Redmond Cavan M. | Director | Option Exercise | A | 5.10 | 6,520 | 33,252 | 6,520 | |
Jun 19 2017 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | A | 5.10 | 50,000 | 255,000 | 50,000 | |
Jun 19 2017 | OCX | OncoCyte Corp | KINGSLEY ALFRED D | Director | Option Exercise | A | 5.10 | 16,300 | 83,130 | 16,300 | |
Jun 19 2017 | OCX | OncoCyte Corp | BAILEY DON M | Director | Option Exercise | A | 5.10 | 20,000 | 102,000 | 20,000 | |
Jun 19 2017 | OCX | OncoCyte Corp | BAILEY DON M | Director | Option Exercise | A | 5.10 | 6,520 | 33,252 | 6,520 | |
Jun 19 2017 | OCX | OncoCyte Corp | Arno Andrew | Director | Option Exercise | A | 5.10 | 20,000 | 102,000 | 20,000 | |
Jun 19 2017 | OCX | OncoCyte Corp | Arno Andrew | Director | Option Exercise | A | 5.10 | 6,520 | 33,252 | 6,520 | |
Feb 22 2017 | OCX | OncoCyte Corp | MECHEM KRISTINE C. | VP of Marketing | Option Exercise | A | 4.70 | 67,500 | 317,250 | 67,500 | |
Feb 22 2017 | OCX | OncoCyte Corp | HESTERBERG LYNDAL K. | Sr VP, Research & D ... | Option Exercise | A | 4.70 | 14,400 | 67,680 | 14,400 | |
Feb 22 2017 | OCX | OncoCyte Corp | ANNETT WILLIAM | President and CEO | Option Exercise | A | 4.70 | 225,000 | 1,057,500 | 250,000 | |
Feb 22 2017 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Option Exercise | J | 3.25 | 212,500 | 690,625 | 212,500 | |
Feb 22 2017 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Option Exercise | X | 3.25 | 425,000 | 1,381,250 | 1,113,461 | |
Feb 22 2017 | OCX | OncoCyte Corp | BROADWOOD PARTNERS, L.P. | 10% Owner | Buy | X | 3.25 | 425,000 | 1,381,250 | 3,056,680 | 2.6 M to 3.1 M (+16.15 %) |
Oct 19 2016 | OCX | OncoCyte Corp | BAILEY DON M | Director | Option Exercise | A | 3.25 | 230,769 | 749,999 | 230,769 |